{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T23:53:10Z","timestamp":1726444390026},"publisher-location":"Boston, MA","reference-count":136,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781461289654"},{"type":"electronic","value":"9781461317135"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1988]]},"DOI":"10.1007\/978-1-4613-1713-5_7","type":"book-chapter","created":{"date-parts":[[2011,9,27]],"date-time":"2011-09-27T04:42:50Z","timestamp":1317098570000},"page":"231-252","source":"Crossref","is-referenced-by-count":8,"title":["Interferon therapy for lymphoproliferative disorders"],"prefix":"10.1007","author":[{"given":"Mark S.","family":"Roth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth A.","family":"Foon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"7_CR1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs A, Lindenman J: Virus interference: I. The interferon. Proc R Soc Lond Biol 147:258\u2013267, 1957.","journal-title":"Proc R Soc Lond Biol"},{"key":"7_CR2","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.4049\/jimmunol.125.5.2353","volume":"125","author":"WE Stewart II","year":"1980","unstructured":"Stewart WE II, Blalock JE, Burke DC, et al: Interferon nomenclature. J Immunol (letters to the editor) 125:2353, 1980.","journal-title":"J Immunol"},{"key":"7_CR3","first-page":"1","volume-title":"Novel Approaches to Cancer Chemotherapy","author":"WR Fleischmann","year":"1984","unstructured":"Fleischmann WR, Klimpel GR, Tyring SK, Voss WR, Baron S: Interferon and cancer: Current use and novel approaches. In: Sunkara PS (ed): Novel Approaches to Cancer Chemotherapy, Orlando, Academic Press, 1984, pp 1\u201322."},{"key":"7_CR4","first-page":"17","volume":"695","author":"PB Sehgal","year":"1982","unstructured":"Sehgal PB: The interferon gene. Biochim Biophys Acta 695:17\u201333, 1982.","journal-title":"Biochim Biophys Acta"},{"key":"7_CR5","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1002\/1097-0142(19841201)54:2+<2770::AID-CNCR2820541425>3.0.CO;2-0","volume":"54","author":"EC Borden","year":"1984","unstructured":"Borden EC: Progress toward therapeutic application of interferons, 1979\u20131983. Cancer 54:2770\u20132776, 1984.","journal-title":"Cancer"},{"key":"7_CR6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1200\/JCO.1984.2.3.221","volume":"2","author":"MJ Hawkins","year":"1984","unstructured":"Hawkins MJ, Borden EC, Merritt JA, et al: Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans. J Clin Oncol 2:221\u2013226, 1984.","journal-title":"J Clin Oncol"},{"key":"7_CR7","first-page":"138","volume":"35","author":"K Cantell","year":"1977","unstructured":"Cantell K, Hirvonen S: Preparation of human leukocyte interferon for clinical use. Texas Rep Biol Med 35:138\u2013144, 1977.","journal-title":"Texas Rep Biol Med"},{"key":"7_CR8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/scientificamerican0883-36","volume":"249","author":"S Pestka","year":"1983","unstructured":"Pestka S: The purification and manufacture of human interferons. Sci Am 249:37\u201343, 1983.","journal-title":"Sci Am"},{"key":"7_CR9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/0076-6879(81)78159-X","volume":"78","author":"LS Lin","year":"1981","unstructured":"Lin LS, Stewart WE II: Purification of human leukocyte interferon by two-dimensional Polyacrylamide gel electrophoresis. Methods Enzymol 78:481, 1981.","journal-title":"Methods Enzymol"},{"key":"7_CR10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0076-6879(81)78160-6","volume":"78","author":"K Berg","year":"1981","unstructured":"Berg K, Heron I: Antibody affinity chromatography of human leukocyte interferon. Methods Enzymol 78:487, 1981.","journal-title":"Methods Enzymol"},{"key":"7_CR11","doi-asserted-by":"crossref","unstructured":"Epstein LB: Interferon-gamma: Success, structure and speculation. Nature 295\u2013454, 1982.","DOI":"10.1038\/295453a0"},{"key":"7_CR12","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1073\/pnas.78.3.1601","volume":"78","author":"YK Yip","year":"1981","unstructured":"Yip YK, Pang RH, Urban C, Vilcek J: Partial purification and characterization of human gamma (immune) interferon. Proc Natl Acad Sci USA 78:1601\u20131605, 1981.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7_CR13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1984.2.4.336","volume":"2","author":"JM Kirkwood","year":"1984","unstructured":"Kirkwood JM, Ernstoff MS: Interferons in the treatment of human cancer. J Clin Oncol 2:336\u2013352, 1984.","journal-title":"J Clin Oncol"},{"key":"7_CR14","first-page":"580","volume":"3","author":"EM Bonnern","year":"1984","unstructured":"Bonnern EM, Spiegel RJ: Interferon-\u03b1: Current status and future promise. J Biol Resp Modif 3:580\u2013598, 1984.","journal-title":"J Biol Resp Modif"},{"key":"7_CR15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJM198401053100107","volume":"301","author":"SD Auerbuch","year":"1984","unstructured":"Auerbuch SD, Austin HA, Sherwin SA, et al: Acute interstitial nephritis with nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N Engl J Med 301:32\u20135, 1984.","journal-title":"N Engl J Med"},{"key":"7_CR16","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1001\/jama.1982.03330190025025","volume":"248","author":"SA Sherwin","year":"1982","unstructured":"Sherwin SA, Knost JA, Fein S, et al: A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248:2461\u20136, 1982.","journal-title":"JAMA"},{"key":"7_CR17","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/1097-0142(197808)42:2+<946::AID-CNCR2820420718>3.0.CO;2-K","volume":"42","author":"HM Golomb","year":"1978","unstructured":"Golomb HM: Hairy cell leukemia: An unusual lymphoproliferative disease. A study of 24 patients. Cancer 42:946\u2013956, 1978.","journal-title":"Cancer"},{"key":"7_CR18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198401053100104","volume":"310","author":"JR Quesada","year":"1984","unstructured":"Quesada JR, Reuben J, Manning JT, Hirsch EM, Gutterman JY: Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 310:15\u201318, 1984.","journal-title":"N Engl J Med"},{"key":"7_CR19","first-page":"207","volume":"3","author":"JR Quesada","year":"1984","unstructured":"Quesada JR, Hersh EM, Gutterman JU: Treatment of hairy cell leukemia with alpha interferon (abstract). Proc Am Soc Clin Oncol 3:207, 1984.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"7_CR20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V68.2.493.493","volume":"68","author":"JR Quesada","year":"1986","unstructured":"Quesada JR, Hersh EM, Manning JT, et al: Treatment of hairy cell leukemia with recombinant \u03b1-interferon. Blood 68:493\u2013497, 1986.","journal-title":"Blood"},{"key":"7_CR21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V65.3.644.644","volume":"65","author":"MJ Ratain","year":"1985","unstructured":"Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K: Treatment of hairy cell leukemia with recombinant alpha2 interferon. Blood 65:644\u20138, 1985.","journal-title":"Blood"},{"key":"7_CR22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood.V65.4.1017.1017","volume":"65","author":"AD Jacobs","year":"1985","unstructured":"Jacobs AD, Champlin RE, Golde DW: Recombinant \u03b1-2-interferon for hairy cell leukemia. Blood 65:1017\u20131020, 1985.","journal-title":"Blood"},{"key":"7_CR23","first-page":"791","volume":"69","author":"JA Thompson","year":"1985","unstructured":"Thompson JA, Brady J, Kidd P, Fefer A: Recombinant \u03b1\u20132-interferon in the treatment of hairy cell leukemia. Cancer Treat Rep 69:791\u20133, 1985.","journal-title":"Cancer Treat Rep"},{"key":"7_CR24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0002-9343(86)90705-9","volume":"80","author":"KA Foon","year":"1986","unstructured":"Foon KA, Maluish AE, Abrams PG, et al: Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia: Therapeutic and immunologic results. Am J Med 80:351\u2013356, 1986.","journal-title":"Am J Med"},{"key":"7_CR25","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1365-2141.1985.tb07480.x","volume":"60","author":"CP Worman","year":"1985","unstructured":"Worman CP, Catovsky D, Bevan PC, et al: Interferon is effective in hairy-cell leukemia. Br J Haem 60:759\u2013763, 1985.","journal-title":"Br J Haem"},{"issue":"1","key":"7_CR26","first-page":"1985","volume":"66","author":"T Habermann","year":"2009","unstructured":"Habermann T, Hoagland H, Chang M, Phylidy R: A phase II trial of alpha recombinant interferon in hairy cell leukemia in patients with advanced disease (abstract). Blood (suppl 1) 66:2009, 1985.","journal-title":"Blood"},{"key":"7_CR27","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/1097-0142(19860415)57:8+<1681::AID-CNCR2820571309>3.0.CO;2-N","volume":"57","author":"S Castaigne","year":"1986","unstructured":"Castaigne S, Sigaux F, Cantell K, et al: Interferon alpha in the treatment of hairy cell leukemia. Cancer 57:1681\u20131684, 1986.","journal-title":"Cancer"},{"key":"7_CR28","first-page":"163","volume":"5","author":"M Ratain","year":"1986","unstructured":"Ratain M, Golomb H, Vardiman J, et al: Durability of reponses to \u03b1\u20132-interferon in advanced hairy cell leukemia (abstract). Proc Am Soc Clin Oncol 5:163, 1986.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"7_CR29","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","volume":"49","author":"The non-Hodgkin\u2019s lymphoma pathologic classification project","year":"1982","unstructured":"The non-Hodgkin\u2019s lymphoma pathologic classification project: National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas. Summary and description of a working formulation for clinical use. Cancer 49:2112\u20132135, 1982.","journal-title":"Cancer"},{"key":"7_CR30","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1056\/NEJM197812282992608","volume":"299","author":"TC Merigan","year":"1978","unstructured":"Merigan TC, Sikora K, Bredden JH, Levy R, Rosenberg SA: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin\u2019s lymphoma. N Engl J Med 299:1449\u20131453, 1978.","journal-title":"N Engl J Med"},{"key":"7_CR31","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood.V58.4.712.712","volume":"58","author":"AC Louie","year":"1981","unstructured":"Louie AC, Gallagher JG, Sikora K, Levy R, Rosenbery SA, Merigan TC: Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin\u2019s lymphomas. Blood 58:712\u2013718, 1981.","journal-title":"Blood"},{"key":"7_CR32","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM198411013111803","volume":"311","author":"KA Foon","year":"1984","unstructured":"Foon KA, Sherwin SA, Abrams PG: Treatment of advanced non-Hodgkin\u2019s lymphoma with recombinant leukocyte A interferon. N Engl J Med 311:1148\u20131152, 1984.","journal-title":"N Engl J Med"},{"key":"7_CR33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.1986.4.2.128","volume":"4","author":"MJ O\u2019Connell","year":"1986","unstructured":"O\u2019Connell MJ, Colgan JP, Oken MM, Ritts RE, Kay NE, Itri LM: Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin\u2019s lymphomas and chronic lymphocytic leukemia. J Clin Oncol 4:128\u2013136, 1986.","journal-title":"J Clin Oncol"},{"key":"7_CR34","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/1097-0142(19850915)56:6<1305::AID-CNCR2820560614>3.0.CO;2-N","volume":"56","author":"SJ Horning","year":"1985","unstructured":"Horning SJ, Merigan TC, Krown SE, et al: Human interferon alpha in malignant lymphoma and Hodgkin\u2019s disease. Cancer 56:1305\u20131310, 1985.","journal-title":"Cancer"},{"issue":"I","key":"7_CR35","first-page":"182a","volume":"64","author":"RD Leavitt","year":"1984","unstructured":"Leavitt RD, Kaplan R, Ozer H: Low dose alpha-3 interferon treatment for low grade non-Hodgkin\u2019s lymphoma (abstract). Blood (Supplement I) 64:182a, 1984.","journal-title":"Blood"},{"key":"7_CR36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-93-3-399","volume":"93","author":"JU Gutterman","year":"1980","unstructured":"Gutterman JU, Blumenschein GR, Alexanian R: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93:399\u2013406, 1980.","journal-title":"Ann Intern Med"},{"key":"7_CR37","first-page":"54","volume":"2","author":"RD Leavitt","year":"1983","unstructured":"Leavitt RD, Ratanatharathorn V, Ozer H, Rudnick S, Ferraresi R: A phase II study of recombinant alpha 2 interferon in patients with malignant lymphoma with unfavorable histology (abstract). Proc Am Soc Clin Oncol 2:54, 1983.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"7_CR38","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-101-4-484","volume":"101","author":"PA Bunn","year":"1984","unstructured":"Bunn PA, Foon KA, Ihde DC: Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas. An Intern Med 101:484\u20137, 1984.","journal-title":"An Intern Med"},{"key":"7_CR39","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","volume":"57","author":"PA Bunn","year":"1986","unstructured":"Bunn PA, Idhe DC, Foon, KA: The role of recombinant interferon alpha-2a in the therapy of cutaneous T-cell lymphomas. Cancer, 57:1689\u20131695, 1986.","journal-title":"Cancer"},{"key":"7_CR40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7326\/0003-4819-103-1-101","volume":"103","author":"RP Gale","year":"1985","unstructured":"Gale RP, Foon KA: Chronic lymphocytic leukemia, recent advances in biology and treatment. Ann Intern Med 103:101\u2013120, 1985.","journal-title":"Ann Intern Med"},{"key":"7_CR41","first-page":"112","volume":"36","author":"JL Misset","year":"1982","unstructured":"Misset JL, Mythe G, Gastiaburu J, et al: Treatment of leukemias and lymphomas by interferons: Phase II trial of chronic lymphoid leukemia by human interferon alpha. Biomed Pharmacother 36:112\u20136, 1982.","journal-title":"Biomed Pharmacother"},{"key":"7_CR42","first-page":"113","volume":"23","author":"A Huang","year":"1982","unstructured":"Huang A, Laszlo J, Brenckman W: Lymphoblastoid interferon (wellferon) trial in chronic lymphocytic leukemia. Proc Am Assoc Cancer Res 23:113, 1982.","journal-title":"Proc Am Assoc Cancer Res"},{"key":"7_CR43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0002-9343(85)90429-2","volume":"78","author":"KA Foon","year":"1985","unstructured":"Foon KA, Bottino G, Abrams PG: Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 78:216\u2013220, 1985.","journal-title":"Am J Med"},{"key":"7_CR44","first-page":"62","volume":"211a","author":"H Ozer","year":"1983","unstructured":"Ozer H, Leavit R, Ratanatharathorn V: Experience in the use of DNA alpha-2 interferon in the treatment of malignant lymphoma (abstract). Am Soc Hematol 62:211a, 1983.","journal-title":"Am Soc Hematol"},{"key":"7_CR45","first-page":"310","volume":"4","author":"RS Schulof","year":"1985","unstructured":"Schulof RS, Lloyd MI, Stallings JJ, et al: Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia: In vivo effects on autologous antitumor immunity. J Biol Response Mod 4:310\u2013323, 1985.","journal-title":"J Biol Response Mod"},{"key":"7_CR46","first-page":"1078","volume-title":"Hematology","author":"D Bergsagel","year":"1983","unstructured":"Bergsagel D: Plasma cell myeloma. In: Williams W, Beutler E, Ersleu A, Lichtman M (eds): Hematology, New York, McGraw Hill, 1983, pp 1078\u20131099."},{"key":"7_CR47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(79)90770-0","volume":"1","author":"H Mellstedt","year":"1979","unstructured":"Mellstedt H, Bjorkholm M, Johansson B, Ahre A, Holm G, Strander H: Interferon therapy in myelomatosis. Lancet 1:245\u20138, 1979.","journal-title":"Lancet"},{"key":"7_CR48","first-page":"242","volume":"2","author":"M Bjorkholm","year":"1983","unstructured":"Bjorkholm M: Daily low dose interferon versus intermittent high dose melphalan\/ prednisone treatment in multiple myeloma (abstract). Proc Am Soc Clin Oncol 2:242, 1983.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"7_CR49","first-page":"161","volume":"21","author":"EF Osserman","year":"1980","unstructured":"Osserman EF, Sherman WH, Alexanian R, Gutterman J: Preliminary results of the American Cancer Society (ACS) sponsored trial of human leukocyte interferon (IF) in multiple myeloma (MM) (abstract). Am Assoc Can Res 21:161, 1980.","journal-title":"Am Assoc Can Res"},{"key":"7_CR50","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/1097-0142(19860415)57:8+<1685::AID-CNCR2820571310>3.0.CO;2-0","volume":"57","author":"R Ohno","year":"1986","unstructured":"Ohno R, Kimura K: Treatment of multiple myeloma with recombinant interferon alpha-2a. Cancer 57:1685\u20131688, 1986.","journal-title":"Cancer"},{"key":"7_CR51","volume-title":"A Phase II trial of rDNA\u03b12-interferon in multiple myeloma","author":"J Costanzi","year":"1984","unstructured":"Costanzi J, Ozer H, Scarffe H: A Phase II trial of rDNA\u03b12-interferon in multiple myeloma. Presented at the International Symposium on Progress and Controversies in Multiple Myeloma, Padua, Italy, April 12, 1984."},{"issue":"I","key":"7_CR52","first-page":"183a","volume":"64","author":"JR Quesada","year":"1984","unstructured":"Quesada JR, Alexanian R, Gutterman JU: Induction of remission and restoration of serum immunoglobulins in multiple myeloma with recombinant DNA-derived Interferon (rIFN\u03b1A) (abstract). Blood (supplement I) 64:183a, 1984.","journal-title":"Blood"},{"key":"7_CR53","first-page":"495","volume":"69","author":"J Wagstaff","year":"1985","unstructured":"Wagstaff J, Loynds P, Scarffe JH: Phase II study of rDNA human alpha-2 interferon in multiple myeloma. Cancer Treat Rep 69:495\u2013498, 1985.","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"7_CR54","doi-asserted-by":"crossref","first-page":"213a","DOI":"10.1182\/blood.V66.1.213.213","volume":"66","author":"DC Case","year":"1985","unstructured":"Case DC, Sonneborn HL, Paul SO, et al: Phase II study of rDNA alpha-2 interferon (Intron A) in patients with multiple myeloma utilizing an escalating induction phase (abstract). Blood (Suppl 1), 66:213a, 1985.","journal-title":"Blood"},{"key":"7_CR55","first-page":"613","volume":"3","author":"RH Clark","year":"1984","unstructured":"Clark RH, Dimitrov NV, Axelson JA, Charamella LJ: Leukocyte interferon as a possible biological response modifier in lymphoproliferative disorders resistant to standard therapy. J Biol Resp Modif 3:613\u2013619, 1984.","journal-title":"J Biol Resp Modif"},{"key":"7_CR56","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1182\/blood.V65.5.1039.1039","volume":"65","author":"RE Champlin","year":"1985","unstructured":"Champlin RE, Golde DW: Chronic myelogenous leukemia: Recent advances. Blood 65:1034\u20131047, 1985.","journal-title":"Blood"},{"issue":"1","key":"7_CR57","first-page":"209a","volume":"66","author":"M Talpaz","year":"1985","unstructured":"Talpaz M, Kantarjian H, McCredie MJ, et al: Clinical study of human alpha interferon in chronic myelogenous leukemia (abstract). Blood (Suppl 1) 66:209a, 1985.","journal-title":"Blood"},{"key":"7_CR58","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7326\/0003-4819-99-6-789","volume":"99","author":"M Talpaz","year":"1983","unstructured":"Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JU: Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 99:789\u2013792, 1983.","journal-title":"Ann Intern Med"},{"key":"7_CR59","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM198604243141701","volume":"314","author":"M Talpaz","year":"1986","unstructured":"Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU: Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 314:1065\u20131069, 1986.","journal-title":"N Engl J Med"},{"issue":"1","key":"7_CR60","first-page":"176a","volume":"64","author":"T Velu","year":"1984","unstructured":"Velu T, Delwiche F, Flument J, Monsieur R, Stryckmans P, Wybran J: Therapy of essential thrombocythemia with human \u03b12 recombinant interferon (abstract). Blood (Supplement 1) 64:176a, 1984.","journal-title":"Blood"},{"key":"7_CR61","first-page":"634","volume":"41","author":"NO Hill","year":"1982","unstructured":"Hill NO, Pardue A, Khan A, Aleman C, Hilario R, Hill JM: Clinical trials of human leukocyte interferon in malignancy. Texas Rep Biol Med 41:634\u2013638, 1982.","journal-title":"Texas Rep Biol Med"},{"key":"7_CR62","first-page":"23","volume":"11","author":"NO Hill","year":"1981","unstructured":"Hill NO, Pardue A, Khan A, Aleman C, Dorn G, Hill JM: Phase I human leukocyte interferon trials in cancer and leukemia. J Clin Hem Onco 11:23\u201325, 1981.","journal-title":"J Clin Hem Onco"},{"key":"7_CR63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00265387","volume":"9","author":"AZ Rohatiner","year":"1982","unstructured":"Rohatiner AZ, Balkwill FR, Griffin DB, Malpas JS, Lister TA: A phase I study of human lymphoblastoid interferon administered by continuous intravenous infusion. Cancer Chemother Pharmocol 9:97\u2013102, 1982.","journal-title":"Cancer Chemother Pharmocol"},{"key":"7_CR64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/BF00257419","volume":"11","author":"AZ Rohatiner","year":"1983","unstructured":"Rohatiner AZ, Balkwill FR, Malpas JS, Lister TA: Experience with human lymphoblastoid interferon in acute myelogenous leukemia. Cancer Chemother Pharmacol 11:56\u201358, 1983.","journal-title":"Cancer Chemother Pharmacol"},{"key":"7_CR65","first-page":"62","volume":"205a","author":"RD Leavitt","year":"1983","unstructured":"Leavitt RD, Duffey P, Wiernik PH: A phase I\/II study of recombinant leukocyte-A interferon in previously treated acute leukemia (abstract). Am Soc Hematol 62:205a, 1983.","journal-title":"Am Soc Hematol"},{"key":"7_CR66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-4684-1170-6_4","volume-title":"Interferon and Cancer","author":"BRG Williams","year":"1983","unstructured":"Williams BRG: Biochemical actions of interferon. In: Sikora K (ed): Interferon and Cancer, New York, Plenum Press, 1983, pp 33\u201352."},{"key":"7_CR67","first-page":"65","volume":"5","author":"S Feinstein","year":"1985","unstructured":"Feinstein S, Traub A, Lazar A, Mizrahi A, Teitz Y: Studies on cell binding and internalization of human lymphoblastoid interferon. J IFN Res 5:65\u20137, 1985.","journal-title":"J IFN Res"},{"key":"7_CR68","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1172\/JCI112480","volume":"77","author":"AS Lau","year":"1986","unstructured":"Lau AS, Hannigan GE, Freedman MH, Williams BR: Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. J Clin Invest 77:1632\u20131638, 1986.","journal-title":"J Clin Invest"},{"key":"7_CR69","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0042-6822(79)90462-8","volume":"94","author":"LA Ball","year":"1979","unstructured":"Ball LA: Induction of 2\u2032\u20135\u2032-oligoadenylate synthetase activity and a new protein by Chick interferon. Virology 94:282\u2013296, 1979.","journal-title":"Virology"},{"key":"7_CR70","first-page":"281","volume-title":"The Enzymes vol XV","author":"LA Ball","year":"1982","unstructured":"Ball LA: 2\u2032\u20135\u2032-oligoadenylat synthetase, In: PD Boyer (ed): The Enzymes vol XV. New York Academic Press 1982, pp 281\u2013313."},{"key":"7_CR71","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1073\/pnas.80.16.4904","volume":"80","author":"G Merlin","year":"1983","unstructured":"Merlin G, Chebath J, Benech P, Metz R, Revel M: Molecular cloning and sequence of partial cDNA for interferon-induced (2\u2032\u20135\u2032 oligo(A) synthetase mRNA from human cells. Proc Natl Acad Sci USA 80:4904\u20134908, 1983.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7_CR72","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1749-6632.1980.tb20649.x","volume":"350","author":"M Revel","year":"1980","unstructured":"Revel M, Kimchi A, Shulman L, et al: Role of interferon induced enzymes in the antiviral and antimitogenic effects of interferon. Ann NY Acad Sci 350:349\u2013472, 1980.","journal-title":"Ann NY Acad Sci"},{"key":"7_CR73","doi-asserted-by":"crossref","first-page":"8237","DOI":"10.1016\/S0021-9258(17)39460-7","volume":"260","author":"JR Bischoff","year":"1985","unstructured":"Bischoff JR, Samuel CE: Mechanism of interferon action. J Biol Chem 260:8237\u20138239, 1985.","journal-title":"J Biol Chem"},{"key":"7_CR74","first-page":"587","volume":"1","author":"A Schattner","year":"1981","unstructured":"Schattner A, Merlin G, Wallach D, et al: Monitoring of interferon therapy by assay of 2\u2032, 5\u2032-oligoisoadenylate synthetase in human peripheral white blood cells. J IFN Res; 1:587\u2013594, 1981.","journal-title":"J IFN Res"},{"key":"7_CR75","first-page":"191","volume":"5","author":"JA Merritt","year":"1985","unstructured":"Merritt JA, Borden EC, Ball LA: Measurement of 2\u2032, 5\u2032-oligadenylate synthetase in patients receiving interferon-alpha. J IFN Res 5:191\u2013198, 1985.","journal-title":"J IFN Res"},{"key":"7_CR76","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/ijc.2910200405","volume":"20","author":"FR Balkwill","year":"1977","unstructured":"Balkwill FR, Oliver RTD: Growth inhibitory effects of interferon on normal and malignant human haemopoietic cells. Int J Cancer 20:500\u2013505, 1977.","journal-title":"Int J Cancer"},{"key":"7_CR77","first-page":"4948","volume":"42","author":"EC Borden","year":"1982","unstructured":"Borden EC, Hogan TF, Voelkel JG: Comparative antiproliferative activity in vitro of natural interferons a and \u00df for diploid and transformed human cells. Cancer Res 42:4948\u20134953, 1982.","journal-title":"Cancer Res"},{"key":"7_CR78","first-page":"55","volume":"11","author":"KC Chadha","year":"1981","unstructured":"Chadha KC, Srivastava BI: Comparison of the antiproliferative effects of human fibroblast and leukocyte interferons on various leukemic cell lines. J Clin Hem Onc 11:55\u201360, 1981.","journal-title":"J Clin Hem Onc"},{"key":"7_CR79","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.1983.1.3.217","volume":"1","author":"SE Salmon","year":"1983","unstructured":"Salmon SE, Durie BG, Young L, Liu RM, Trown P, Stebbing N: Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217\u2013225, 1983.","journal-title":"J Clin Oncol"},{"key":"7_CR80","first-page":"147","volume":"5","author":"H Denz","year":"1985","unstructured":"Denz H, Lechleitner M, Marth CH, Daxenbichler G, Gastl G, Braunsteiner H: Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematologic malignancies. J IFN Res 5:147\u2013157, 1985.","journal-title":"J IFN Res"},{"key":"7_CR81","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0008-8749(80)90041-6","volume":"49","author":"J Blalock","year":"1980","unstructured":"Blalock J, Georgiades JE, Langford MP, Johnson HM: Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon. Cell Immun 49:390\u2013394, 1980.","journal-title":"Cell Immun"},{"key":"7_CR82","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1126\/science.493995","volume":"206","author":"JS Horoszewicz","year":"1979","unstructured":"Horoszewicz JS, Leong SS, Carter WS: Noncycling tumor cells are sensitive targets for the antiproliferative activity of human interferon. Science 206:1091\u20131093, 1979.","journal-title":"Science"},{"key":"7_CR83","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1073\/pnas.77.3.1471","volume":"77","author":"AA Creasey","year":"1980","unstructured":"Creasey AA, Batholomew JC, Merigan TC: Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 77:1471\u20131475, 1980.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7_CR84","first-page":"614","volume":"40","author":"RS Bart","year":"1980","unstructured":"Bart RS, Porzio NR, Kopf AW, Vilcek JT, Cheng EH, Farcet Y: Inhibition of growth of B-16 murine malignant melanoma by exogenous interferon. Cancer Res 40:614, 1980.","journal-title":"Cancer Res"},{"key":"7_CR85","first-page":"993","volume":"54","author":"GB Rossi","year":"1975","unstructured":"Rossi GB, Marcheglani M, Matarese GP and Gresser I: Brief communication: Inhibitory effect of interferon on multiplication of friend leukemia cells in vivo. J Natl Cancer Inst 54:993, 1975.","journal-title":"J Natl Cancer Inst"},{"key":"7_CR86","first-page":"871","volume":"3","author":"JL Crane","year":"1978","unstructured":"Crane JL, Glasgow LA, Kern ER, Youngner JS: Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. J Natl Cancer Inst 3:871, 1978.","journal-title":"J Natl Cancer Inst"},{"key":"7_CR87","first-page":"231","volume":"516","author":"I Greseer","year":"1978","unstructured":"Greseer I, Tovey M: Antitumor effects of interferon. Biochem Biophys Acta 516:231\u2013247, 1978.","journal-title":"Biochem Biophys Acta"},{"key":"7_CR88","first-page":"125","volume":"19","author":"Y Yoshitake","year":"1976","unstructured":"Yoshitake Y, Kishida T, Esaki K, Kawamata J: Antitumor effects of interferon on transplanted tumors in congenitally athymic nude mice. Giken J 19:125\u20137, 1976.","journal-title":"Giken J"},{"key":"7_CR89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ijc.2910300217","volume":"30","author":"FR Balkwill","year":"1982","unstructured":"Balkwill FR, Moodie EM, Freedman V, Frantes KH: Human interferon inhibits the growth of established human breast tumors in the nude mouse. Int J Cancer 30:231\u2013235, 1982.","journal-title":"Int J Cancer"},{"key":"7_CR90","first-page":"97","volume-title":"Advances in Cancer Research","author":"I Gresser","year":"1972","unstructured":"Gresser I: Antitumor effects of interferon. In: Klein G, Weinhouse S (eds): Advances in Cancer Research, New York, Academic Press, 16:97\u2013140, 1972."},{"key":"7_CR91","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4049\/jimmunol.134.4.2783","volume":"134","author":"T Barlozzari","year":"1985","unstructured":"Barlozzari T, Leonhardt J, Wiltrout RH, Herberman RB, Reynolds CW: Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol 134:2783\u20132789, 1985.","journal-title":"J Immunol"},{"key":"7_CR92","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1126\/science.7025208","volume":"214","author":"RB Herberman","year":"1981","unstructured":"Herberman RB, Ortaldo JR: Natural killer cells: Their role in defenses against diseases. Science 214:24\u201330, 1981.","journal-title":"Science"},{"key":"7_CR93","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/277221a0","volume":"277","author":"RB Herberman","year":"1979","unstructured":"Herberman RB, Ortaldo JR, Bonnard G: Augmentation by interferon of human natural and antibody-dependent cell mediated cytotoxicity. Nature 277:221\u2013223, 1979.","journal-title":"Nature"},{"key":"7_CR94","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF00922756","volume":"1","author":"RB Herberman","year":"1981","unstructured":"Herberman RB, Ortaldo JR, Rubinstein M, Pestka S: Augmentation of natural and antibody-dependent cell mediated cytotoxicity by pure human leukocyte interferon. J Clin Immunol 1:149\u2013153, 1981.","journal-title":"J Clin Immunol"},{"key":"7_CR95","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0008-8749(82)90208-8","volume":"67","author":"RB Herberman","year":"1982","unstructured":"Herberman RB, Ortaldo JR, Mantovani A, Hobbs DS, Kung H-F, Pesta S: Effect of human recombinant interferon on cytotoxic activity of natural killer cells and monocytes. Cell Immunol 67:160\u2013167, 1982.","journal-title":"Cell Immunol"},{"key":"7_CR96","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/282417a0","volume":"282","author":"JR Huddleston","year":"1979","unstructured":"Huddleston JR, Merigan TC, Oldstone MBA: Induction and kinetics of natural killer cells in humans following interferon therapy. Nature 282:417\u2013419, 1979.","journal-title":"Nature"},{"key":"7_CR97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-97-1-1","volume":"97","author":"EC Borden","year":"1982","unstructured":"Borden EC, Holland JF, Dao T, et al: Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med 97:1\u20136, 1982.","journal-title":"Ann Intern Med"},{"key":"7_CR98","first-page":"418","volume":"2","author":"AE Maluish","year":"1983","unstructured":"Maluish AE, Ortaldo JR, Sherwin SA, Oldham RK, Herberman RB: Function in patients receiving natural leukocyte interferon. J Biol Resp Modif 2:418\u2013427, 1983.","journal-title":"J Biol Resp Modif"},{"key":"7_CR99","first-page":"470","volume":"2","author":"AE Maluish","year":"1983","unstructured":"Maluish AE, Leavitt R, Sherwin SA, Oldham RK, Herberman RB: Effects of recombinant interferon-\u03b1 on immune function in cancer patients. J Biol Resp Modif 2:470\u201381, 1983.","journal-title":"J Biol Resp Modif"},{"key":"7_CR100","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1172\/JCI111905","volume":"75","author":"BS Edwards","year":"1985","unstructured":"Edwards BS, Merritt JA, Fuhlbrigge RC, Bordon EC: Low doses of interferon alpha result in more effective clinical natural killer cell activation. J Clin Invest 75:1908\u20131913, 1985.","journal-title":"J Clin Invest"},{"key":"7_CR101","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.4049\/jimmunol.124.5.2157","volume":"124","author":"S Targan","year":"1980","unstructured":"Targan S, Dorey F: Interferon activation of \u2018pre-spontaneous killer\u2019 cells (pre-sk) and alteration in kinetics of lysis of both \u2018pre-sk\u2019 and active sk cells. J Immunol 124:2157, 1980.","journal-title":"J Immunol"},{"key":"7_CR102","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.4049\/jimmunol.128.6.2514","volume":"128","author":"T Timonen","year":"1982","unstructured":"Timonen T, Ortaldo JR, Herberman RB: Analysis by a single cell cytotoxicity assay of natural killer (NK) cell frequencies among human large granular lymphocytes and of the effects of interferon on their activity. J Immunol 128:2514, 1982.","journal-title":"J Immunol"},{"key":"7_CR103","doi-asserted-by":"crossref","unstructured":"Wright SC, Bonauida B: Role of natural killer cytotoxic factors (NKCF) in the mechanism of NK cell mediated cytotoxicity. In: Herberman RB (ed): NK Cells and Other Natural Effector Cells, New York, Academic Press, pp 961\u2013968.","DOI":"10.1016\/B978-0-12-341360-4.50143-8"},{"key":"7_CR104","first-page":"294","volume":"135","author":"EH Steinhauer","year":"1985","unstructured":"Steinhauer EH, Doyle AT, Kadish AS: Human natural killer cytotoxic factor (NKCF): Role of IFN-OL J Immunol 135:294\u2013299, 1985.","journal-title":"Role of IFN-OL J Immunol"},{"key":"7_CR105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.153.3.569","volume":"153","author":"T Timonen","year":"1981","unstructured":"Timonen T, Ortaldo JR, Herberman RB: Characteristics of large granular lymphocytes and relationship to natural killer and killer cells. J Exp Med 153:569\u2013582, 1981.","journal-title":"J Exp Med"},{"key":"7_CR106","first-page":"1431","volume":"209","author":"MG Masucci","year":"1980","unstructured":"Masucci MG, Sziget R, Klein E, et al: Effect of interferon-\u03b11from E. coli on some cell functions. Science 209:1431\u20135, 1980.","journal-title":"E. coli on some cell functions. Science"},{"key":"7_CR107","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-3083.1980.tb00079.x","volume":"12","author":"JR Ortaldo","year":"1980","unstructured":"Ortaldo JR, Pestka S, Slease RB, Rubinstein M, Herberman RB: Augmentation of human K-cell activity with interferon. Scand J Immunol 12:365\u2013369, 1980.","journal-title":"Scand J Immunol"},{"key":"7_CR108","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.4049\/jimmunol.127.4.1585","volume":"127","author":"P Hokland","year":"1981","unstructured":"Hokland P, Berg K: Interferon enhances the antibody-dependent cellular cytotoxicity of human polymorphonuclear leukocytes. J Immunol 127:1585\u20138, 1981.","journal-title":"J Immunol"},{"key":"7_CR109","first-page":"125","volume-title":"Interferon: Research, Clinical Application, and Regulatory Consideration","author":"JY Djeu","year":"1984","unstructured":"Djeu JY: Regulation of cell functions by interferon. In: Zoon KC, Noguchi PO, Liu T-Y (eds): Interferon: Research, Clinical Application, and Regulatory Consideration, New York, Elsevier, 1984, pp 125\u2013131."},{"key":"7_CR110","first-page":"499","volume":"2","author":"H Ozer","year":"1983","unstructured":"Ozer H, Gavigan M, O\u2019Malley J, et al: Immunomodulation by recombinant interferon-\u03b12 in a phase I trial in patients with lymphoproliferative malignancies. J Biol Resp Modif 2:499\u2013515, 1983.","journal-title":"J Biol Resp Modif"},{"key":"7_CR111","first-page":"127","volume-title":"Cell Functions in Immunity and Inflammation","author":"DL Rosenstreich","year":"1981","unstructured":"Rosenstreich DL: The macrophage. In: Oppenheim JJ, Rosenstreich DL, Potter M (eds): Cell Functions in Immunity and Inflammation. New York, Elsevier, North Holland, 1981, p 127."},{"key":"7_CR112","first-page":"134","volume":"4","author":"S Sone","year":"1985","unstructured":"Sone S, Utsugi T, Shirahama T, Ishii K, Mutsuura S, Mitsumasa O: Induction by interferon-a of tumoridical activity of adherent mononuclear cells from human blood: Monocytes as responder and effector cells. J Biol Resp Modif 4:134\u2013140, 1985.","journal-title":"J Biol Resp Modif"},{"key":"7_CR113","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.4049\/jimmunol.132.5.2436","volume":"132","author":"D Fertsch","year":"1984","unstructured":"Fertsch D, Vogel SN: Recombinant interferons increase macrophage Fc receptor capacity. J Immunol 132:2436\u20132439, 1984.","journal-title":"J Immunol"},{"key":"7_CR114","first-page":"1940","volume":"45","author":"JR Sadlik","year":"1985","unstructured":"Sadlik JR, Hoyer M, Leyko MA, et al: Lymphocyte supernatant-induced human monocyte tumoricidal activity: Dependence on the presence of \u03b3-interferon. Cancer Research 45:1940\u20131945, 1985.","journal-title":"Cancer Research"},{"key":"7_CR115","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.4049\/jimmunol.127.5.2146","volume":"127","author":"B Harfast","year":"1981","unstructured":"Harfast B, Huddleston JR, Casali P, Merigan TC, Oldstone MB: Inteferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. J Immunol 127:2146\u20132150, 1981.","journal-title":"J Immunol"},{"key":"7_CR116","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4049\/jimmunol.130.3.1215","volume":"130","author":"MA Rodriguez","year":"1983","unstructured":"Rodriguez MA, Prinz WA, Sibbitt WL, Bankhurst AD, Williams RC: a-interferon increases immunoglobulin production in cultured human mononuclear leukocytes. J Immunol 130:1215\u20131219, 1983.","journal-title":"J Immunol"},{"key":"7_CR117","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0008-8749(81)90454-8","volume":"64","author":"YS Choi","year":"1981","unstructured":"Choi YS, Lim KH, Sanders FK: Effect of interferon-a on pokeweed mitogen-induced differentiation of human peripheral blood B lymphocytes. Cell Immunol 64:20\u201328, 1981.","journal-title":"Cell Immunol"},{"key":"7_CR118","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.4049\/jimmunol.129.3.1099","volume":"129","author":"TA Fleisher","year":"1982","unstructured":"Fleisher TA, Attallah AM, Tosato O, Blaese RM, Greene WC: Inhibition of human polyclonal immunoglobulin synthesis. J Immunol 129:1099\u20131103, 1982.","journal-title":"J Immunol"},{"key":"7_CR119","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3181\/00379727-141-36868","volume":"141","author":"W Braun","year":"1972","unstructured":"Braun W, Levy HB: Interferon preparations as modifiers of immune responses. Proc Soc Exp Biol Med 141:769\u2013773, 1972.","journal-title":"Proc Soc Exp Biol Med"},{"key":"7_CR120","first-page":"85","volume-title":"Inteferon, Volume 2: Interferons and the Immune System","author":"G Sonnefeld","year":"1984","unstructured":"Sonnefeld G: Effects of interferon on antibody formation. In: Vilcek J, DeMaeyer E (eds): Inteferon, Volume 2: Interferons and the Immune System, Amsterdam, 1984, Elsevier Science Publishers pp 85\u201399."},{"key":"7_CR121","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.4049\/jimmunol.117.4.1370","volume":"117","author":"I Heron","year":"1976","unstructured":"Heron I, Berg K, Cantell K: Regulatory effect of interferon on T-cells in vitro. J Immunol 117:1370\u20131373, 1976.","journal-title":"J Immunol"},{"key":"7_CR122","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1084\/jem.155.6.1610","volume":"155","author":"D Fradelizi","year":"1982","unstructured":"Fradelizi D, Gresser I: Interferon inhibits the generation of allospecific suppressor T lymphocytes. J Exp Med 155:1610\u20131622, 1982.","journal-title":"J Exp Med"},{"key":"7_CR123","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.4049\/jimmunol.131.5.2301","volume":"131","author":"HW Schnaper","year":"1983","unstructured":"Schnaper HW, Aune T, Pierce C: Suppressor T cell activation by human leukocyte interferon. J Immunol 131:2301\u20132306, 1983.","journal-title":"J Immunol"},{"key":"7_CR124","first-page":"113","volume-title":"Interferons and The Immune System","author":"I Gresser","year":"1984","unstructured":"Gresser I: The effect of interferon on the expression of surface antigens. In: Vilcek J, DeMaeyer E (eds): Interferons and The Immune System. Elsevier Amsterdam, Science Publishers, 1984, pp 113\u2013132."},{"key":"7_CR125","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1073\/pnas.75.12.6215","volume":"75","author":"I Heron","year":"1978","unstructured":"Heron I, Hokland M, Berg K: Enhanced expression of B2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci 75:6215, 1978.","journal-title":"Proc Natl Acad Sci"},{"key":"7_CR126","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4049\/jimmunol.132.1.240","volume":"132","author":"VE Kelley","year":"1984","unstructured":"Kelley VE, Fier W, Strom TB: Cloned human interferon-\u03b3, but not interferon-\u03b2 or \u03b1, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J Immunol 132:240, 1984.","journal-title":"J Immunol"},{"key":"7_CR127","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/eji.1830131003","volume":"13","author":"D Wallach","year":"1983","unstructured":"Wallach D: The HLA proteins and a related protein of 28 KdA are preferentially induced by interferon-\u03b3 in human WISH cells; Eur J Immunol 13:794, 1983.","journal-title":"Eur J Immunol"},{"key":"7_CR128","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1073\/pnas.79.14.4395","volume":"79","author":"SC Meur","year":"1982","unstructured":"Meur SC, Schlossman SF, Reinherz EL: Clonal analysis of human cytotoxic T-lympho-cytes T-4+ and T-8+ effector T-cells recognize products of different major histocompat-ability complex regions. Proc Natl Acad Sci USA 79:4395, 1982.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7_CR129","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1083\/jcb.87.2.319","volume":"87","author":"RL Erikson","year":"1980","unstructured":"Erikson RL, Purchio AF, Erikson E, Collet MS, Brugge JS: Molecular events in cells transformed by Rous sacrcoma virus. J Cell Biol 87:319\u2013325, 1980.","journal-title":"J Cell Biol"},{"key":"7_CR130","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/MCB.3.9.1656","volume":"3","author":"SL Lin","year":"1983","unstructured":"Lin SL, Garber EA, Wang E, et al: Reduced synthesis of pp 60 and expression of the transformation-related phenotype in interferon-treated Rous sarcoma virus-transformed rat cells. Mol Cell Biol 3:1656\u20131664, 1983.","journal-title":"Mol Cell Biol"},{"key":"7_CR131","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1073\/pnas.82.15.4891","volume":"82","author":"CH Dani","year":"1985","unstructured":"Dani CH, Mechti N, Piechaczyk M, Lebleu B, Jeanteur PH, Blanchard JM: Increased rate of degradation of c-myc mRNA in interferon-treated Daudi cells. Proc Natl Acad Sci, 82:4891\u20134899, 1985.","journal-title":"Proc Natl Acad Sci"},{"key":"7_CR132","first-page":"64","volume":"175a","author":"DR Strayer","year":"1984","unstructured":"Strayer DR, Gillespie DH, Bressuer J, Brodsky I: Oncogene expression decreased in two patients treated with interferons (abstract). Blood (supplement I) 64:175a, 1984.","journal-title":"Blood (supplement I)"},{"key":"7_CR133","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood.V68.1.293.293","volume":"68","author":"G Semenzato","year":"1986","unstructured":"Semenzato G, Pizzolo G, Agostini C, et al: \u03b1-interferon activates the natural killer system in patients with hairy cell leukemia. Blood 68:293\u2013296, 1986.","journal-title":"Blood"},{"key":"7_CR134","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1182\/blood.V67.4.1077.1077","volume":"67","author":"CR Faltynek","year":"1986","unstructured":"Faltynek CR, Princier GL, Rusetti FW, Maluish AE, Abrams PG, Foon KA: Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases. Blood 67:1077\u20131082, 1986.","journal-title":"Blood"},{"key":"7_CR135","first-page":"20","volume":"26","author":"BL Samuels","year":"1985","unstructured":"Samuels BL, Brownstein BH, Golomb HM: Effect of interferons on patterns of protein synthesis in hairy cells (abstract). Proc Am Assoc Can Res 26:20, 1985.","journal-title":"Proc Am Assoc Can Res"},{"key":"7_CR136","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood.V67.2.458.bloodjournal672458","volume":"67","author":"L Baldini","year":"1986","unstructured":"Baldini L, Cortelezzi A, Polli N, et al: Human recombinant interferon \u03b1\u20132C enhances the expression of class II HLA antigens on hairy cells. Blood 67:458\u2013464, 1986.","journal-title":"Blood"}],"container-title":["Cancer Treatment and Research","Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4613-1713-5_7.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T21:47:44Z","timestamp":1712958464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4613-1713-5_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988]]},"ISBN":["9781461289654","9781461317135"],"references-count":136,"URL":"https:\/\/doi.org\/10.1007\/978-1-4613-1713-5_7","relation":{},"ISSN":["0927-3042"],"issn-type":[{"type":"print","value":"0927-3042"}],"subject":[],"published":{"date-parts":[[1988]]}}}